drugset / Trial / NCT02833688

Effects of Dexmedetomidine on the Liver Injury After Hepatectomy

NCT02833688 ↗

Phase 4 Completed 70 enrolled Chinese PLA General Hospital
RandomizedParallel-groupSingle-blindPrevention

Summary

To investigate whether dexmedetomidine reduce liver injury after hepatectomy. During hepatectomy, surgeons always took inflow occlusion to reduce blood loss with Pringle maneuver. A few clinical studies had shown dexmedetomidine could reduce ischaemia/reperfusion (IR) injury caused by the secretion of reactive oxygen species and inflammatory cytokines. Glutathione-S-transferase (GST) was a sensitive and specific marker for hepatic injury in several studies before. So the investigator decided to use it as the primary endpoint. Besides, in our center, there are some liver resection surgeries that didn't need occlusion. So it can serve the best placebo for determine the the actual effect of dexmedetomidine on the IR injury in further subgroup analysis.

Timeline

Start
2016-08-02
Primary completion
2017-01-26
Completion
2017-01-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexmedetomidine Other / unclassified 0.5 ug/kg Other

Indications